Brian D. Lehmann
Brian D. Lehmann
Adresse e-mail validée de vanderbilt.edu
Titre
Citée par
Citée par
Année
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
BD Lehmann, JA Bauer, X Chen, ME Sanders, AB Chakravarthy, Y Shyr, ...
The Journal of clinical investigation 121 (7), 2750-2767, 2011
36112011
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, EWT Wong, ...
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773 (8), 1263-1284, 2007
22152007
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ...
Clinical cancer research 19 (19), 5533-5540, 2013
5162013
Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection
BD Lehmann, B Jovanović, X Chen, MV Estrada, KN Johnson, Y Shyr, ...
PloS one 11 (6), e0157368, 2016
4832016
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets
JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ...
Cancer discovery 4 (2), 232-245, 2014
3282014
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
BD Lehmann, JA Pietenpol
The Journal of pathology 232 (2), 142-150, 2014
3122014
Senescence-associated exosome release from human prostate cancer cells
BD Lehmann, MS Paine, AM Brooks, JA McCubrey, RH Renegar, R Wang, ...
Cancer research 68 (19), 7864-7871, 2008
3072008
Subtyping of triple‐negative breast cancer: implications for therapy
VG Abramson, BD Lehmann, TJ Ballinger, JA Pietenpol
Cancer 121 (1), 8-16, 2015
2662015
New strategies for triple-negative breast cancer—deciphering the heterogeneity
IA Mayer, VG Abramson, BD Lehmann, JA Pietenpol
Clinical cancer research 20 (4), 782-790, 2014
2562014
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
BD Lehmann, JA Bauer, JM Schafer, CS Pendleton, L Tang, KC Johnson, ...
Breast Cancer Research 16 (4), 406, 2014
2062014
TNBCtype: a subtyping tool for triple-negative breast cancer
X Chen, J Li, WH Gray, BD Lehmann, JA Bauer, Y Shyr, JA Pietenpol
Cancer informatics 11, CIN. S9983, 2012
1692012
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
LS Steelman, PM Navolanic, ML Sokolosky, JR Taylor, BD Lehmann, ...
Oncogene 27 (29), 4086-4095, 2008
1512008
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
KE Hutchinson, D Lipson, PJ Stephens, G Otto, BD Lehmann, PL Lyle, ...
Clinical Cancer Research 19 (24), 6696-6702, 2013
1322013
Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer
KD Yu, R Zhu, M Zhan, AA Rodriguez, W Yang, S Wong, A Makris, ...
Clinical cancer research 19 (10), 2723-2733, 2013
1232013
Targeting prostate cancer based on signal transduction and cell cycle pathways
JT Lee, BD Lehmann, DM Terrian, WH Chappell, F Stivala, M Libra, ...
Cell cycle 7 (12), 1745-1762, 2008
1202008
Patient-derived breast tumor xenografts facilitating personalized cancer therapy
MD Landis, BD Lehmann, JA Pietenpol, JC Chang
Breast Cancer Research 15 (1), 201, 2013
1092013
A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells
BD Lehmann, JA McCubrey, HS Jefferson, MS Paine, WH Chappell, ...
Cell cycle 6 (5), 595-605, 2007
1022007
Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer
ME Feigin, SD Akshinthala, K Araki, AZ Rosenberg, LB Muthuswamy, ...
Cancer research 74 (11), 3180-3194, 2014
952014
Triple-negative breast cancer: molecular subtypes and new targets for therapy
BD Lehmann, JA Pietenpol, AR Tan
American Society of Clinical Oncology Educational Book 35 (1), e31-e39, 2015
882015
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance
JA McCubrey, LS Steelman, RA Franklin, SL Abrams, WH Chappell, ...
Advances in enzyme regulation 47, 64, 2007
852007
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20